Takeda Leads Uncluttered Race For First Norovirus Therapy
Executive Summary
Although norovirus infections are implicated in roughly 200,000 deaths per year, there are only four candidates in clinical development, Datamonitor Healthcare notes. This may be due partly to challenges posed by the virus' strain diversity and a lack of epidemiologic data.
You may also be interested in...
Takeda Cements Norovirus Lead Through Vaccine Trial Start
Takeda has initiated dosing in the first field trial globally with a candidate vaccine for norovirus, maintaining its clear development lead in the area.
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.
A Good Choice To Have: Scrip’s Interview With Viking CEO Brian Lian
Still a clinical-stage company, Viking is studying promising candidates for both obesity and MASH in Phase II, but may need to prioritize one while partnering the other.